Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA

CHEST Journal 2026 Open access

Read full text
Authors: A. Schwartz, Ofer Jacobowitz, Samuel A. Mickelson, Mitchell B. Miller, Arie Oliven, Victor Certal, Martin L. Hopp, David Winslow, Tod Huntley, Nathan E. Nachlas, Luu Pham, David W. Eisele
+6 more M.B. Gillespie, Brian H. Weeks, Eric G. Lovett, John Shen, Anil K. Malhotra, Jaclyn Maurer
DOI: 10.1016/j.chest.2025.11.057
Cited by: 2
References: 38

Abstract

BACKGROUND: Targeted proximal hypoglossal nerve stimulation was shown to improve sleep-disordered breathing, sleep architecture, and quality of life (QOL) with a favorable safety profile over 1 year in the Targeted Hypoglossal Stimulation 3 (THN3) randomized controlled trial. Herein, THN3 proximal hypoglossal nerve stimulation (pHGNS) 3-year safety and efficacy are profiled with reference to distal hypoglossal nerve stimulation (dHGNS) from the Stimulation Therapy for Apnea Reduction (STAR) trial. RESEARCH QUESTION: What are the long-term safety and efficacy of pHGNS, and how do they compare with dHGNS? STUDY DESIGN AND METHODS: . Participants completing the prespecified 3-year visit were analyzed. Outcomes included adverse events, AHI, Oxygen Desaturation Index, percentage of sleep time with oxygen saturation

Fields of Study & Subjects

Obstructive Sleep Apnea Research Neuroscience of respiration and sleep Cardiovascular Syncope and Autonomic Disorders

Publication details

Journal / source
CHEST Journal
Publisher
Elsevier BV
Volume
169
Issue
5
Pages
1357–1370
Publication date
12 February 2026
Language
EN